ISSN 2407-2230 | E-ISSN 1907-3062 | Universa Medicina content is searchable on DOAJ, Google Scholar, and OAI

Ki-67 marker useful for classification of malignant invasive ductal breast cancer

Irmawati Hassan, Twidy Tarcisia, Agnestina Agnestina, Santoso Cornain, I Made Nasar
Submission date: Monday, 07 December 2015
Published date: Monday, 07 December 2015


Breast cancer is an important health problem in the world. Uncontrolled cell proliferation represents a malignant characteristic of neoplasia such as breast cancer, and can be examined immunohistochemically by measuring the Ki-67 proliferative marker. The objective of this study was to determine the role of Ki-67 for classification of the degree of malignancy in women with invasive ductal breast cancer.

A cross-sectional study was conducted on 20 women with invasive ductal breast cancer. The samples were immuno-histochemically tested for Ki-67 using anti-Ki-67 primary antibody. The Ki-67 proliferative index was determined by enumerating the proportion of Ki-67 positive nuclei among the total number of cells in ten areas observed at 400x magnification, using a 20% cut-off value to distinguish between low and high proliferative indices. Statistical analysis was by means of the chi-square test.
Seventy five persent of the high grade malignancies had a high Ki-67 proliferative index (>20%), while only 12.5% of the low grade malignancies had a high Ki-67 index (>20%). The difference in grade malignancy was statistically significant (p=0.022), whereas tumor size was not associated with a statistically significant difference in Ki-67 index (p=0.648).

The study showed that invasive ductal breast cancer with high Ki-67 index was significantly associated with high grade of malignacy. The high Ki-67 marker index can be used for classification of the grade of malignancy of invasive ductal breast cancer.


Ki-67 proliferative index; grading; ductal invasive breast cancer

Full Text:



Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Cancer global statistic. CA Cancer J Clin 2011;61:69-90.

Direktorat Jendral Pelayanan Medik Departemen Kesehatan R.I. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia, Yayasan Kanker Indonesia. Kanker di Indonesia tahun 1988, 1998, 2008: data histopatologik. Jakarta: Direktorat Jendral Pelayanan Medik Departemen Kesehatan R.I.;2009.

Allen DC. Histopathology reporting: guidelines for surgical cancer. 3rd ed. London: Springer; 2013.

Trihia H, Murray S, Price K, Gelbert RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its associations with grading systems, clinical parameters, and other prognostic factors – a surrogate marker? Cancer 2003;97:1321-31.

Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011;13:R22.

Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol 2011;22:500-2. doi:10.1093/annonc/mdq732.

Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.

Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 2005. doi: 10.1002/path. 1711520407.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annal Oncol 2009;20:1319-29.

De Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano MS, Durberq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11: 174-83.

Bonnefoi H, Underhill C, Inggo R, Cameron D. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in clinic? Eur J Cancer 2009;45:1733-43.

Colloza M, Sidoni A, Piccart-Gebhart M. Value of Ki-67 in breast cancer: the debate is still open. Lancet Oncol 2010;11:414-5.

Nishimura R, Osaka T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010;1:747-54.

Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours, pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC;2003.

Wiesner FC, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009;18:135-41.

Nishimura R, Osaka T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010;17:269-75.

Patil AV, Singhai R, Bhamre RS, Patil VW. Ki-67 biomarker in breast cancer of Indian woman. N Am J Med Sci 2011;3:119-28.

Loly D. Hubungan imunoekspresi Ki-67 dengan beberapa parameter prognostic histopatologik karsinoma payudara invasif di tiga Laboratorium Patologi Anatomi Sumatera Barat (thesis). Padang: F.K. Unandalas;2011.

Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, et al. Comparative validation of the SP6 antibody to Ki-67 in breast cancer. J Clin Pathol 2010;63:800-4.


  • There are currently no refbacks.

Copyright (c) 2015 Universa Medicina

Creative Commons License
Universa Medicina by Faculty of Medicine, Trisakti University is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at